TFP
GERM

Tilia Fiduciary Partners’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Tilia Fiduciary Partners’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-183
Closed -$5K – 565
2022
Q1 		$5K Hold
183
– – ﹤0.01% 471
2021
Q4 		$7K Buy
+183
New +$6.86K 0.01% 446

Other funds holding GERM

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tilia Fiduciary Partners's GERM Position: Q2 2022 in Review

Tilia Fiduciary Partners sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q2 2022, closing a stake of 183 shares — an estimated $5K sold.

Tilia Fiduciary Partners first reported a position in GERM in Q4 2021 and held it in 2 quarters. The position peaked at $7K in Q4 2021. 25 funds tracked by Wall St. Rank hold GERM as of Q2 2022.

  • Tilia Fiduciary Partners reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q2 2022 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 183 Amplify Treatments, Testing and Advancements ETF shares in Q2 2022, an estimated $5K.
  • Tilia Fiduciary Partners first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2021 and held it in 2 quarters.
  • Tilia Fiduciary Partners's Amplify Treatments, Testing and Advancements ETF position peaked at $7K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q2 2022.

Based on Tilia Fiduciary Partners's 13F filing for Q2 2022, filed 1 Aug 2022.